Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Current Assets (2016 - 2025)

Fate Therapeutics (FATE) has disclosed Current Assets for 14 consecutive years, with $208.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 28.5% year-over-year to $208.7 million, compared with a TTM value of $208.7 million through Dec 2025, down 28.5%, and an annual FY2025 reading of $208.7 million, down 28.5% over the prior year.
  • Current Assets was $208.7 million for Q4 2025 at Fate Therapeutics, down from $221.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $804.3 million in Q1 2021 and bottomed at $208.7 million in Q4 2025.
  • Average Current Assets over 5 years is $441.5 million, with a median of $393.3 million recorded in 2023.
  • The sharpest move saw Current Assets soared 286.23% in 2021, then plummeted 37.06% in 2025.
  • Year by year, Current Assets stood at $633.4 million in 2021, then decreased by 20.74% to $502.1 million in 2022, then tumbled by 33.97% to $331.5 million in 2023, then decreased by 11.95% to $291.9 million in 2024, then fell by 28.5% to $208.7 million in 2025.
  • Business Quant data shows Current Assets for FATE at $208.7 million in Q4 2025, $221.3 million in Q3 2025, and $230.4 million in Q2 2025.